Who we are
We reimagine medicine to improve and extend people’s lives. We use innovative science and technology to address some of society’s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. We also aim to reward those who invest their money, time and ideas in our company.
Our values and behaviors
- Engage our people
- Strive for patients
- Live our purpose
- Be open
- Be self-aware
- Create clarity
- Serve others
- Own your actions
- Be honest
- Have courage
- Do what’s right
At Novartis, we use science-based innovation to adress some of society’s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.
The Innovative Medicines Division has two business units:
Novartis Oncology focuses on patented treatments for a variety of cancers and rare diseases.
Novartis Pharmaceuticals focuses on patented treatments in multiple disease areas to enhance health outcomes for patients and offer solutions to healthcare providers.
The Sandoz Division offers patients and healthcare professionals high-quality, affordable generics and biosimilars.
Novartis Business services (NBS)
consolidates support services across our organization, helping drive efficiency, simplification, standardization and quality.
Novartis technical operations (NTO)
is responsible for making our innovative medicines, devices and Sandoz products, and delivering them to our customers across the world.
support the enterprise in specific areas of expertise, including finance, human resources, legal, communications and ethics, risk and compliance.
Research and development (R&D)
The Novartis Institutes for BioMedical Research (NIBR) is the innovation engine of Novartis. NIBR focuses on discovering new drugs that can change the practice of medicine.
The Global Drug Development (GDD) organization oversees the development of new medicines discovered by our researchers and partners.
The greatest strength of Novartis is our people, whose diversity, energy and creativity are crucial to our success.
Our products address most major disease areas and are sold in approximately 155 countries around the world. Our manufacturing facilities produced 72 billion treatments in 2020.
We develop and produce innovative medicines to address patient needs in disease areas where our experience and knowledge have the potential to produce transformative treatments.
- Cardiovascular, renal and metabolism
- Immunology, hepatology and dermatology
- Infectious Diseases
We also offer about 1 000 generic and biosimilar medicines covering a broad range of therapeutic areas. They can bring substantial savings to patients and healthcare systems, and help improve access to healthcare.